Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Glucagon

- PMLiVE

Novo Nordisk’s Victoza fails type 1 diabetes trial

Danish firm’s hopes dashed by latest data

- PMLiVE

Jardiance is first diabetes drug to improve CV outcomes

Lilly/Boehringer drug could gain market share boost from new data

- PMLiVE

Intarcia’s diabetes implant beats Merck’s Januvia in trial

New injection-less therapy could revolutionise diabetes treatment

- PMLiVE

Diabetes rates jump by 60% in UK

Comes as new analysis also reveals that 10% of the NHS GP drugs budget spent on the disease

- PMLiVE

Healthcare gets more independence in Google restructuring

New ‘Alphabet’ company will put tech giant’s health ventures centre-stage

- PMLiVE

Diabetes costs jump again in England

Cost of treating the disease rising as prices and patients increase in number

Sanofi reception

Sanofi and Evotec to work together on diabetes and cancer

Willfocus on beta cell-modulating diabetes treatments and immuno-oncology therapies

Boehringer Ingelheim headquarters

Boehringer returns to growth in first half

German firm back on track after a tough sales period

Sanofi reception

Sanofi keeps Toujeo price level with Lantus in UK

French firm hoping to maintain market share with its next-gen insulin product

- PMLiVE

New iPad app helps schizophrenia patients

Research shows the app ‘Wizard’ could aid memory and independence

Lilly brings Glucagon app to Android devices

Follows app's 2012 debut in iPhone version

- PMLiVE

Merck hopes for another Keytruda with new immunotherapy deal

US firm signs pact with cCAM Biotherapeutics for cancer research

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links